“Response Rate in HCV Genotype 3 in Interferon Based Direct Acting Anti-Viral Therapy”

Authors

  • Dr. Abdur Rehman, Dr. Mairya Manzoor, Dr. Munazza Nazir, Dr. Noman Kareem Qureshi, Dr. Fatima Ibrar, Dr. Zarnab Munir

Abstract

Objective:

To assess the frequency of rapid and end treatment response rates in HCV (genotype 3) infected patients taking Sofosbuvir in combination with ribavirin and peg-interferons for a period of 3 months.

Study design: Descriptive cross sectional study

Setting: Medicine Department, Combined Military Hospital(CMH), Kharian and Quetta

Duration of study: 6 Months from 9th Feb 2016 to 8th Aug 2016

Methodology

This study was conducted in Gastroenterology Dept.of CMH Kharian from  9th February 2016 to 31st  May 2016 and in CMH Quetta from 1st  June  2016  to  8th  August  2016. All patients with HCV RNA PCR. +ve with genotype3, were included in the study. Patients with other HCV Genotypes and hepatitis viruses were excluded from the study. They were given PegINF 180µg with Sofosbuvir 400mg and Ribavirin weight based for 3 months.  PCR was done at 4 weeks and 12 weeks of treatment to see Rapid virological response and end of treatment response i.e. RVR and ETR respectively. Data was analyzed by spss version 22.

Results: - In this study, out of 165 cases, 67.88 %( n=112) were between 18-50 years of age whereas 32.12%(n=53) were between 51-80 years of age, Mean±SD 43.30+12.62 years. 40%(n=66) were male whereas 60%(n=99) were females, frequency of rapid and end treatment response rates in HCV (genotype 3) infected patients taking Sofosbuvir in combination with ribavirin and peginterferons for a period of 3 months was calculated as 25.45%(n=42) for rapid and 86.67%(n=143) for end of treatment.

Conclusion: Frequency of rapid and end treatment response rates in HCV (genotype 3) infected patients taking Sofosbuvir in combination with ribavirin and peg interferons for period of 3 months are higher.

Published

2021-08-01

How to Cite

Dr. Abdur Rehman, Dr. Mairya Manzoor, Dr. Munazza Nazir, Dr. Noman Kareem Qureshi, Dr. Fatima Ibrar, Dr. Zarnab Munir. (2021). “Response Rate in HCV Genotype 3 in Interferon Based Direct Acting Anti-Viral Therapy”. Drugs and Cell Therapies in Hematology, 10(2), 188–193. Retrieved from http://dcth.org/index.php/journal/article/view/869

Issue

Section

Articles